secwatch.observer — SEC 8-K summary
======================================

Issuer:     Celldex Therapeutics, Inc. (CLDX)
CIK:        0000744218
Form:       8-K
Filed at:   2022-07-18T23:59:59+00:00
Accession:  0001104659-22-080483
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Celldex settles Kolltan merger litigation; agrees to up to $80M in milestone payments
--------------------------------------------------------------------------------

- Celldex pays $15M upfront; future milestones replaced with $12.5M on successful Phase II of CDX-0159 (barzolvolimab) and $52.5M on first regulatory approval.
- Litigation in Delaware Court of Chancery to be dismissed with prejudice; each side bears own fees.
- Prior milestone obligations under the 2016 Kolltan merger agreement are superseded; remaining payments at Celldex's election in cash or stock.
- Settlement releases all claims related to the merger agreement, including those in the lawsuit.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/744218/000110465922080483/0001104659-22-080483-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/744218/000110465922080483/tm2221215d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-080483

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer